National safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey

被引：0

作者：

Dursun, A. ^{[1
]}

Bavbek, S. ^{[2
]}

Misirligil, Z. ^{[2
]}

Erdener, F. ^{[3
]}

Buyukozturk, S. ^{[4
]}

Aydin, O. ^{[2
]}

Gemicioglu, B. ^{[5
]}

Bayrak, P. ^{[6
]}

Erkekol, Oner F. ^{[1
]}

Yildirim, Z. ^{[7
]}

Cilli, A. ^{[8
]}

Boz, Bingol A. ^{[9
]}

Alpaydyn, Ozgen A. ^{[10
]}

Karakoc, G. ^{[11
]}

Gorguner, M. ^{[12
]}

Karakaya, G. ^{[13
]}

Isik, R. ^{[14
]}

Sapan, N. ^{[15
]}

Bakirtas, A. ^{[16
]}

机构：

[1] Ataturk Chest Dis & Thorac Surg Training & Res Ho, Allergy Clin, Ankara, Turkey

[2] Ankara Univ, Sch Med, Dept Resp Med, Div Clin Immunol & Allergy, TR-06100 Ankara, Turkey

[3] Istanbul Training & Res Hosp, Dept Internal Med, Istanbul, Turkey

[4] Istanbul Univ, Istanbul Med Sch, Dept Internal Med, Div Allerg Dis, Istanbul, Turkey

[5] Istanbul Univ, Cerrahpasa Med Sch, Dept Resp Med, Istanbul, Turkey

[6] Celal Bayar Univ, Sch Med, Dept Internal Med, Div Clin Immunol & Allergy, Manisa, Turkey

[7] Fatih Univ, Sch Med, Dept Resp Med, Ankara, Turkey

[8] Akdeniz Univ, Sch Med, Dept Resp Med, TR-07058 Antalya, Turkey

[9] Akdeniz Univ, Sch Med, Dept Pediat, Div Allergy, TR-07058 Antalya, Turkey

[10] Celal Bayar Univ, Sch Med, Dept Resp Med, Manisa, Turkey

[11] Cukurova Univ, Sch Med, Dept Pediat, Div Allergy, Adana, Turkey

[12] Ataturk Univ, Sch Med, Dept Resp Med, Erzurum, Turkey

[13] Hacettepe Univ, Sch Med, Dept Resp Med, Adult Allergy Unit, Ankara, Turkey

[14] Seyhan Training & Res Hosp, Adult Allergy Unit, Adana, Turkey

[15] Uludag Univ, Sch Med, Dept Pediat, Div Allergy, Bursa, Turkey

[16] Gazi Univ, Sch Med, Dept Pediat, Div Allergy, Ankara, Turkey

来源：

ALLERGY | 2011年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

1786

引用

页码：675 / 676

页数：2

共 50 条

[11] Omalizumab: A Review of its Use in Patients with Severe Persistent Allergic Asthma
Kate McKeage
Drugs, 2013, 73 : 1197 - 1212
[12] Characteristics of post-marketing studies and their contribution to post-marketing safety measures in Japan
Kanmuri K.
Narukawa M.
Pharmaceutical Medicine, 2014, 28 (2) : 67 - 73
[13] Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma
Ohta, Ken
Miyamoto, Terumasa
Amagasaki, Taro
Yamamoto, Manabu
RESPIROLOGY, 2009, 14 (08) : 1156 - 1165
[14] THE SAFETY OF OMALIZUMAB THERAPY IN A PATIENT WITH SEVERE PERSISTENT ALLERGIC ASTHMA AND HEPATITIS C
Antonicelli, Leonardo
Stagnozzi, Giorgia
Giuliodoro, Simona
Abbruzzetti, Alessandra
Massaccesi, Chiara
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2009, 103 (03) : 269 - 270
[15] Real-life safety and efficacy of omalizumab in Japanese patients with severe allergic asthma who were subjected to dosing table revision or expansion: A post-marketing surveillance
Asano, Koichiro
Sumi, Kazuya
Yoshisue, Hajime
Nakamura, Noriko
Nagasaki, Makoto
Sasajima, Takayoshi
Matsumoto, Hisako
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2020, 64
[16] Omalizumab In The Treatment Of Severe Persistent Bakers Asthma
Ruiz Garcia, M.
Fernandez Nieto, M.
Manso Alonso, L.
Sastre Dominguez, J.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB179 - AB179
[17] Omalizumab for the treatment of severe persistent allergic asthma
Jones, J.
Shepherd, J.
Hartwell, D.
Harris, P.
Cooper, K.
Takeda, A.
Davidson, P.
HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 31 - 39
[18] A Combination of Tezepelumab and Omalizumab for Severe Persistent Asthma
Saleh, Z.
Kanaan, J.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
[19] Omalizumab in the treatment of severe persistent bakers asthma
Ruiz Garcia, M.
Fernandez-Nieto, M.
Manso Alonso, L.
Sastre Dominguez, J.
ALLERGY, 2010, 65 : 655 - 655
[20] The safety of oseltamivir in pregnancy: an updated review of post-marketing data
Wollenhaupt, Martina
Chandrasekaran, Abhijeeth
Tomianovic, Danitza
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (10) : 1035 - 1042

← 1 2 3 4 5 →